These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34643722)

  • 1. Hydroxyurea Use After Transitions of Care Among Young Adults With Sickle Cell Disease and Tennessee Medicaid Insurance.
    Mathias JG; Nolan VG; Klesges LM; Badawy SM; Cooper WO; Hankins JS; Smeltzer MP
    JAMA Netw Open; 2021 Oct; 4(10):e2128971. PubMed ID: 34643722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxyurea use in patients with sickle cell disease in a Medicaid population.
    Ritho J; Liu H; Hartzema AG; Lottenberg R
    Am J Hematol; 2011 Oct; 86(10):888-90. PubMed ID: 21922530
    [No Abstract]   [Full Text] [Related]  

  • 3. Increasing hydroxyurea use in children with sickle cell disease at Kamuzu Central Hospital, Malawi.
    Mvalo T; Topazian H; Kamthunzi P; Chen J; Kambalame I; Mafunga P; Mumba N; Chiume-Chiphaliwali M; Paseli K; Key N; Gopal S; Hoffman I; Ataga K; Westmoreland K
    Blood Adv; 2018 Nov; 2(Suppl 1):30-32. PubMed ID: 30504195
    [No Abstract]   [Full Text] [Related]  

  • 4. Hydroxyurea treatment in children with sickle cell anemia in Central America and the Caribbean countries.
    Svarch E; Machín S; Nieves RM; Mancia de Reyes AG; Navarrete M; Rodríguez H
    Pediatr Blood Cancer; 2006 Jul; 47(1):111-2. PubMed ID: 16550531
    [No Abstract]   [Full Text] [Related]  

  • 5. When should hydroxyurea be used for children with sickle cell disease?
    Mueller BU
    Pediatrics; 2008 Dec; 122(6):1365-6. PubMed ID: 19047256
    [No Abstract]   [Full Text] [Related]  

  • 6. Hydroxyurea in sickle cell disease.
    Burke SM
    MCN Am J Matern Child Nurs; 1996; 21(4):210. PubMed ID: 8754440
    [No Abstract]   [Full Text] [Related]  

  • 7. Accidental hydroxyurea overdosage in a child with sickle cell anemia: An African experience.
    Nnebe-Agumadu U; Adebayo IA; Nnodu O; Adekile A
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28632. PubMed ID: 32743869
    [No Abstract]   [Full Text] [Related]  

  • 8. High hydroxyurea usage in sickle cell anemia regardless of patient demographics.
    Phan V; Park JA; Dulman R; Lewis A; Briere N; Notarangelo B; Yang E
    Pediatr Blood Cancer; 2024 Feb; 71(2):e30728. PubMed ID: 38069808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxyurea Initiation Among Children With Sickle Cell Anemia.
    Reeves SL; Jary HK; Gondhi JP; Raphael JL; Lisabeth LD; Dombkowski KJ
    Clin Pediatr (Phila); 2019 Nov; 58(13):1394-1400. PubMed ID: 31113236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resolution of cerebral artery stenosis in a child with sickle cell anemia treated with hydroxyurea.
    Grace RF; Su H; Sena L; Poussaint TY; Heeney MM; Gutierrez A
    Am J Hematol; 2010 Feb; 85(2):135-7. PubMed ID: 20052745
    [No Abstract]   [Full Text] [Related]  

  • 11. Expanding the role of hydroxyurea in children with sickle cell disease.
    Rogers ZR; Buchanan GR
    J Pediatr; 2004 Sep; 145(3):287-8. PubMed ID: 15343174
    [No Abstract]   [Full Text] [Related]  

  • 12. Making hydroxyurea affordable for sickle cell disease in Tanzania is essential (HASTE): How to meet major health needs at a reasonable cost.
    Costa E; Tibalinda P; Sterzi E; Leufkens HMG; Makani J; Kaale E; Luzzatto L
    Am J Hematol; 2021 Jan; 96(1):E2-E5. PubMed ID: 32974896
    [No Abstract]   [Full Text] [Related]  

  • 13. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].
    Nkashama GM; Wakamb GK; Mulangu AM; Nkashama GM; Kupa BK; Numbi OL
    Pan Afr Med J; 2015; 21():124. PubMed ID: 26327961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
    Kinney TR; Helms RW; O'Branski EE; Ohene-Frempong K; Wang W; Daeschner C; Vichinsky E; Redding-Lallinger R; Gee B; Platt OS; Ware RE
    Blood; 1999 Sep; 94(5):1550-4. PubMed ID: 10477679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children.
    Strouse JJ; Lanzkron S; Beach MC; Haywood C; Park H; Witkop C; Wilson RF; Bass EB; Segal JB
    Pediatrics; 2008 Dec; 122(6):1332-42. PubMed ID: 19047254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.
    Zimmerman SA; Schultz WH; Davis JS; Pickens CV; Mortier NA; Howard TA; Ware RE
    Blood; 2004 Mar; 103(6):2039-45. PubMed ID: 14630791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Level of utilization and provider-related barriers to the use of hydroxyurea in the treatment of sickle cell disease patients in Jos, North-Central Nigeria.
    Ofakunrin AO; Okpe ES; Afolaranmi TO; Olaosebikan RR; Kanhu PU; Adekola K; Dami N; Sagay AS
    Afr Health Sci; 2021 Jun; 21(2):765-774. PubMed ID: 34795734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxyurea for children with sickle cell disease.
    Heeney MM; Ware RE
    Pediatr Clin North Am; 2008 Apr; 55(2):483-501, x. PubMed ID: 18381097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease.
    Brandow AM; Panepinto JA
    Am J Hematol; 2011 Sep; 86(9):804-6. PubMed ID: 21815183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stroke Recurrence in Nigerian Children With Sickle Cell Disease: Evidence for a Secondary Stroke Prevention Trial.
    Abdullahi SU; DeBaun MR; Jordan LC; Rodeghier M; Galadanci NA
    Pediatr Neurol; 2019 Jun; 95():73-78. PubMed ID: 30952488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.